136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL

Ähnliche Einträge

• 46 | EFFICACY OF RITUXIMAB‐BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH‐RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
  von: M. Dreyling, et al.
  Veröffentlicht: (2025)
• 272 | ACALABRUTINIB IN COMBINATION WITH RITUXIMAB IS HIGHLY EFFECTIVE FRONTLINE TREATMENT FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA
  von: P. Jain, et al.
  Veröffentlicht: (2025)
• 47 | IBRUTINIB AND RITUXIMAB IS SUPERIOR TO IMMUNOCHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA DESPITE LOWER RATES OF MRD NEGATIVITY
  von: D. Lewis, et al.
  Veröffentlicht: (2025)
• 607 | EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB AS FIRST‐LINE TREATMENT FOR MANTLE CELL LYMPHOMA
  von: H. Zhu, et al.
  Veröffentlicht: (2025)
• 45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)
  von: C. Melani, et al.
  Veröffentlicht: (2025)